A Study of SHR-2173 in Participants With Primary IgA Nephropathy

Category Primary study
Registry of Trialsclinicaltrials.gov
Year 2026
This study is a randomized, double-blind, placebo-controlled Phase II clinical trial to evaluate the efficacy and safety of SHR-2173 in patients with Primary IgA Nephropathy(IgAN). The study consists of a screening period, a run-in period, a 48-week double-blind treatment period, and a 12-week follow-up period. Approximately 84 IgAN patients will be included.
Epistemonikos ID: 7bbaff7fa1abb26f84bcec04be75239fbb9c6379
First added on: Jan 23, 2026